NASDAQ:PACBPacific Biosciences of California Stock Price, Forecast & News

Pacific Biosciences of California's stock was trading at $3.44 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PACB stock has increased by 2.3% and is now trading at $3.52. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacific Biosciences of California in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Pacific Biosciences of California.

Pacific Biosciences of California is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Pacific Biosciences of California.

Pacific Biosciences of California (NASDAQ:PACB) issued its quarterly earnings data on Wednesday, May, 6th. The biotechnology company reported ($0.21) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.16) by $0.05. The biotechnology company earned $15.60 million during the quarter, compared to analyst estimates of $20.10 million. Pacific Biosciences of California had a negative net margin of 58.35% and a negative return on equity of 131.21%. View Pacific Biosciences of California's earnings history.

3 Wall Street analysts have issued 1-year target prices for Pacific Biosciences of California's shares. Their forecasts range from $5.00 to $7.00. On average, they anticipate Pacific Biosciences of California's share price to reach $6.00 in the next year. This suggests a possible upside of 70.5% from the stock's current price. View analysts' price targets for Pacific Biosciences of California.

Press coverage about PACB stock has been trending negative on Monday, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Pacific Biosciences of California earned a news sentiment score of -2.6 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutPacific Biosciences of California.

Some companies that are related to Pacific Biosciences of California include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Bio-Rad Laboratories (BIO), Waters (WAT), PerkinElmer (PKI), BIO-TECHNE (TECH), Charles River Laboratories Intl. (CRL), Bruker (BRKR), Luminex (LMNX), Fluidigm (FLDM), Harvard Bioscience (HBIO), aTyr Pharma (LIFE) and BG Medicine (BGMD). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacific Biosciences of California investors own include Illumina (ILMN), Novavax (NVAX), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), Advanced Micro Devices (AMD), ImmunoGen (IMGN), Alibaba Group (BABA), BioCryst Pharmaceuticals (BCRX), FireEye (FEYE) and Micron Technology (MU).

Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB."

Pacific Biosciences of California's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.33%), Capital International Investors (4.41%), Capital World Investors (3.53%), Water Island Capital LLC (3.53%), Weiss Multi Strategy Advisers LLC (2.76%) and State Street Corp (2.33%). Company insiders that own Pacific Biosciences of California stock include James Michael Phillips, Kathy Ordonez, Michael Hunkapiller and Susan K Barnes. View institutional ownership trends for Pacific Biosciences of California.

PACB stock was sold by a variety of institutional investors in the last quarter, including Magnetar Financial LLC, Healthcare of Ontario Pension Plan Trust Fund, Morgan Stanley, Public Sector Pension Investment Board, UBS Group AG, ArrowMark Colorado Holdings LLC, Alliancebernstein L.P., and BNP Paribas Arbitrage SA. Company insiders that have sold Pacific Biosciences of California company stock in the last year include James Michael Phillips, Michael Hunkapiller, and Susan K Barnes. View insider buying and selling activity for Pacific Biosciences of California.

PACB stock was acquired by a variety of institutional investors in the last quarter, including Capital World Investors, Weiss Multi Strategy Advisers LLC, Camber Capital Management LP, Assenagon Asset Management S.A., Capital International Investors, BlackRock Inc., JPMorgan Chase & Co., and Water Island Capital LLC. View insider buying and selling activity for Pacific Biosciences of California.

Shares of PACB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PACB stock can currently be purchased for approximately $3.52.

Pacific Biosciences of California has a market capitalization of $542.33 million and generates $90.89 million in revenue each year. The biotechnology company earns $-84,130,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis. Pacific Biosciences of California employs 401 workers across the globe.

The official website for Pacific Biosciences of California is www.pacb.com.

Pacific Biosciences of California's mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-521-8000 or via email at [email protected]